Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2016 Earnings Results

Arrowhead Pharmaceuticals Beats on EPS, Stock Up 8.31%

Arrowhead Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to an 8.31% increase in their stock price. The positive surprise in EPS indicates that the company is managing its expenses effectively. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.32	N/A	+12.81%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism about their future prospects. They emphasized the importance of their clinical developments.

Management highlighted progress in ongoing clinical trials.

They expressed confidence in their pipeline but acknowledged challenges ahead.

Arrowhead Pharmaceuticals Beats on EPS, Stock Up 8.31%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Beats on EPS, Stock Up 8.31%

Key numbers

Management commentary